Preliminary clinical results of combined 433 megahertz microwave therapy and radiation therapy on patients with advanced cancer

Hornback, Ned B.; Shupe, Robert E.; Shidnia, Homayoon; Joe, B. T.; Sayoc, Edgardo; Marshall, Carol

doi:10.1002/1097-0142(197712)40:6<2854::aid-cncr2820400616>3.0.co;2-l

Cited by 77 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such local heat treatment is now being tested clinically at several institutions with encouraging, but not uniformly successful, results [1][2][3][4][5][6][7]. The goal of local heat therapy is to raise the temperature of the tumor mass to a lethal leve1 [8][9][10] without damaging surrounding normal tissue.…”

Section: Introductionmentioning

confidence: 99%

Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs

Voorhees

Babbs

1982

European Journal of Cancer and Clinical Oncology

106

View full text Add to dashboard Cite

This study was designed to test the hypothesis that vasodilator drugs can enhance selective heating of solid tumors by producing a favorable redistribution of blood flow between tumor and normal tissues. Subcutaneous transmissible venereal tumor implants were heated by inductive diathermy using Helmholtz coils in 8 dogs. The temperature rise in tumor and adjacent muscle was measured before and after giving hydralazine (0.5 mg/kg i.v.). Blood flow to the tumors and underlying muscle was measured with radioactive tracer microspheres. Before hydralazine treatment mean muscle blood flow was about one-third tumor blood flow (0.11  0.02 vs. 0.28  0.09 ml/min/g), and tumor and normal muscle temperatures were not significantly different (40.0  0.6 vs. 39.7  0.l o C). After hydralazine tumor blood flow decreased and muscle blood flow increased in every dog, and selective heating of the tumors became possible. Muscle blood flow averaged 0.67  0.13 ml/min/g, 17 times greater than tumor blood flow, which decreased to 0.04 0.02 ml/min/g. Core tumor temperature was 48.0  0.9 vs. 38.5  0.5 o C for underlying muscle. Blood pressure was maintained at 80  5.7 mmHg. These results demonstrate that adjuvant treatment with vasodilators is a promising technique to increase the temperature difference between tumors and surrounding normal tissues during local heat therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs

Voorhees

Babbs

1982

European Journal of Cancer and Clinical Oncology

106

View full text Add to dashboard Cite

show abstract

“…This type of hyperthermia appears to be effective against both small tumors and the larger tumors that have the poorest response to traditional therapy. When combined with one or more of the standard treatments, such as radiation therapy or chemotherapy, relatively low-dose hyperthermia (42 43 °C) appears to induce a synergistic or additive effect (10)(11)(12)(13).…”

Section: Discussionmentioning

confidence: 99%

“…histology or size (3). Furthermore, chemotherapy (10,11) and radiation therapy (12,13) may be additive or synergistic with hyperthermia.…”

Section: Introductionmentioning

confidence: 99%

Combination radiofrequency hyperthermia and chemotherapy (BCNU) for brain malignancy

Aw¹,

Df²,

Fk³

et al. 1984

J Neuro-Oncol

View full text Add to dashboard Cite

Patients with high-grade primary and metastatic brain malignancies have a median survival time of 3-8 months, regardless of therapy. Because MagnetrodeTM hyperthermia provides safe, deep internal heating without normal-tissue injury, we studied its effects first on the brain and surrounding tissues of rabbits. The normal rabbit brain (n = 26) could be heated to potentially tumoricidal temperatures (42-43 degrees C) without apparent histopathologic or clinical damage to the brain, skull, external eye, subcutaneous tissue or skin. Intracranial pressure did not rise significantly. Using transplanted VX-2 carcinoma, we showed both the safety and potential efficacy of thermochemotherapy (IV BCNU: 14 mg/kg) in the presence of a solid brain tumor. The average maximum brain temperature achieved was 43.06 degrees C. Mean survival from the time of tumor implantation in the treated group (n = 16) was 18.56 days, compared to 9.3 days for untreated controls (n = 30) (p less than .0001). Two patients have been treated with localized brain hyperthermia combined with intravenous BCNU (80 mg/m2) for a total of eight treatments. Maximum normal brain temperature achieved was 40.0 degrees C in Patient #1 and 41.5 degrees C in Patient #2. A tumor temperature of 42.9 degrees C was achieved in Patient #2. Intracranial pressure remained within the upper limits of normal. Swan-Ganz monitoring in Patient #1 revealed a stable cardiac index and mean pulmonary artery pressure with mild fluctuations in the CVP, PAD, and PCW. No increase in chemotherapy toxicity was observed and no normal tissue injury occurred in either patient. We conclude that non-invasive localized radiofrequency hyperthermia to the brain is feasible and can be performed safely in the presence of a solid brain tumor.

show abstract

“…By controlling the phase difference between microwaves radiated from different antennas, we can control the location of peaks and nodes in the electromag-netic field formed by interference patterns in the irradiated space. Hyperthermia using a lower frequency of microwave (e.g., 433 MHz) has been already studied (2) , but it was not combined with phase control. Phase control techniques were demonstrated at 2.45 GHz (3) , but at that frequency, the depth of penetration is too small to be adequate.…”

Section: Introductionmentioning

confidence: 99%

Fundamental Study on Localized Heating in Hyperthermia Using Phase Control of Long-wavelength Microwaves

et al. 2007

View full text Add to dashboard Cite

Hyperthermia is expected to be as an effective treatment method that can contribute to improving a cancer patient's quality of life. At present, two frequency ranges are used in hyperthermia. One is relatively low and the other is in the microwave range. However, side effects, such as burns due to heating healthy cells or physical strain caused invasive surgery, remain major burdens for patients. To resolve these problems, we propose the use of a lower microwave frequency with phase control. In this paper, we present the selection of a suitable frequency, a demonstration experiment, and a corresponding numerical analysis using the selected frequency.To determine a suitable frequency, we calculated the distribution of SAR in a one-dimensional system. It was composed of a muscle layer between air layers and had two plane wave sources synchronized with an appropriate phase difference at the edges. We found a desirable frequency range of several hundreds MHz in which a single SAR peak existed in the muscle layer.We performed heating experiments on a tissue-equivalent phantom made from agar using a frequency of 430 MHz. We used a pair of circular patch antennas to irradiate the phantom and produced phase differences between the antennas by changing the length of the feed cables. Figure 1 shows grayscale images of the temperature distributions inside the phantom after microwave irradiation. Here, (a) and (b) correspond to the phase differences of 0 and π, respectively. As Fig. 1(a) shows, a higher temperature region was found in the center of x2-axis shown in the figure, while it is a lower temperature in the same region of Fig. 1(b).We also performed a numerical simulation in three dimensions under the same conditions as the experiment. Figure 2 shows grayscale images of the electric field distributions for almost the same area as in Fig. 1. The regions of larger field amplitude corresponded well to those of a higher temperature in Fig. 1. The detailed analysis of these calculations revealed that the temperature distribution was attributable to the interference between radiated waves. The manipulation of the temperature distribution by phase controlled irradiation of long-wavelength microwaves was demonstrated. Hironori Namiki * * * Non-memberFor the treatment of cancer using hyperthermia, high frequency electromagnetic fields are used to heat the cancer cells. These electromagnetic fields fall into two general frequency ranges, one relatively low, and the other in the microwave range. Both produce some side effects such as the heating of healthy cells or the impact on the body of invasive surgery required to expose deep-lying cells. To reduce these side reactions, the use of lower microwave frequencies with phase control was proposed. In this paper, we present a very basic study to prove the viability of the proposed scheme. This includes the selection of a suitable frequency, demonstration of localized heating using the selected frequency, and a three-dimensional numerical analysis of the electromagnetic fields in...

show abstract

Preliminary clinical results of combined 433 megahertz microwave therapy and radiation therapy on patients with advanced cancer

Cited by 77 publications

References 34 publications

Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs

Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs

Combination radiofrequency hyperthermia and chemotherapy (BCNU) for brain malignancy

Fundamental Study on Localized Heating in Hyperthermia Using Phase Control of Long-wavelength Microwaves

Contact Info

Product

Resources

About